Promatix is an ALSA Group company using multi-omic insights to develop the next generation of cancer therapeutics
Develops novel immuno-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors
World leader in IgE drugs with a pipeline of therapies to treat solid cancer tumours
Pipeline of first in class oncology drugs leveraging a proprietary database